Evidence map›Paper›PMID 32706456›Full record

ArticlePediatric blood & cancer2020

Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium.

Jonathan Gill, Wendong Zhang, Zhongting Zhang, Michael Roth, Douglas J Harrison, Sudie Rowshan, Stephen Erickson, Gregory Gatto, Raushan Kurmasheva, Peter Houghton and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Canine and murine models of osteosarcoma.Veterinary pathology · 2022
    Review
  3. Advancing therapy for osteosarcoma.Nature reviews. Clinical oncology · 2021
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Jonathan GillDivision of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7796-8632
Wendong ZhangDivision of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Zhongting ZhangDivision of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael RothDivision of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Douglas J HarrisonDivision of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Sudie RowshanRTI International, Research Triangle Park, Durham, North Carolina.
Stephen EricksonRTI International, Research Triangle Park, Durham, North Carolina.
Gregory GattoRTI International, Research Triangle Park, Durham, North Carolina.
Raushan KurmashevaGreehey Children's Cancer Research Institute, University of Texas Health Science Center, San Antonio, Texas.ORCID 0000-0003-3212-2363
Peter HoughtonGreehey Children's Cancer Research Institute, University of Texas Health Science Center, San Antonio, Texas.
Beverly TeicherCancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
Malcolm A SmithCancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
E Anders KolbNemours Center for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, Delaware.
Richard GorlickDivision of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas.
The University of Texas MD Anderson Cancer Center · USRTI International · USNational Cancer Institute · MYThe University of Texas Health Science Center at San Antonio · USNemours Children's Health System · US

Funding

Osteosarcoma: Patient Derived Xenograft Preclinical TestingU01CA199221 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Richard G. Gorlick · 2015 to 2026
$3.8M
NCI NIH HHS CA199221NCI NIH HHS U01 CA199221
6 · The paper itself

Abstract

The pediatric preclinical testing program previously demonstrated activity of eribulin in osteosarcoma patient-derived xenograft (PDX) models. The phase 2 trial in patients with relapsed osteosarcoma failed to meet response endpoints. Eribulin was evaluated in the original and an expanded set of PDX models and tested at multiple dose levels and schedules to evaluate dose-response. Maximal response was observed at the highest dose, consistent with prior results. The alternative schedule generated similar responses. We demonstrate steep dose-response for eribulin in osteosarcoma PDX models, implying that any deviation from achievement of effective concentrations may have a significant impact on activity.

Indexed as

AnimalsApoptosisBone NeoplasmsCell ProliferationChildDrug Evaluation, PreclinicalFuransHumansKetonesMiceOsteosarcomaPolyether PolyketidesTumor Cells, CulturedXenograft Model Antitumor AssayseribulinFuransKetonesPolyether PolyketideseribulinosteosarcomaPDX

Identifiers

PMID32706456
PMCPMC8715715
OpenAlexW3045366833

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.